OM
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Outset Medical, Inc. (OM) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (3.0) | C (2.4) | C (2.5) | C+ (2.8) | C+ (2.6) | C+ (2.7) |
| 2026-11-07 | B- (3.0) | C (2.3) | C (2.5) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-31 | B- (3.0) | C (2.3) | C (2.5) | C- (2.0) | C+ (2.7) | C (2.5) |
| 2026-10-24 | B- (3.0) | C (2.2) | C (2.5) | C- (1.9) | C+ (2.6) | C (2.5) |
| 2026-10-17 | B- (3.0) | C (2.3) | C (2.5) | C- (2.0) | C+ (2.6) | C (2.5) |